The ups and downs of novel antiemetic drugs, part 1: substance P, 5-HT, and the neuropharmacology of vomiting.
Novel antiemetic agents such as the newly approved aprepitant (Emend) target receptors for substance P, known as neurokinin-1 (NK(1)) receptors. When NK(1) receptors are blocked in the vomiting center of the brainstem, chemotherapy-induced emesis is reduced. It is possible that blocking NK(1) receptors elsewhere in the CNS will lead to therapeutic actions in depression and other stress-related disorders.
Stahl
Stephen M
SM
Neuroscience Education Institute, Carlsbad, CA 92009, USA.
D000932:Antiemetics / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D000077608:Aprepitant; D031608:Area Postrema / Q000187:drug effects / Q000502:physiology; D001933:Brain Stem / Q000187:drug effects* / Q000502:physiology; D003866:Depressive Disorder / Q000188:drug therapy; D006801:Humans; D009025:Morpholines / Q000494:pharmacology* / Q000627:therapeutic use; D018040:Receptors, Neurokinin-1 / Q000187:drug effects* / Q000502:physiology; D012701:Serotonin / Q000502:physiology*; D017552:Solitary Nucleus / Q000187:drug effects / Q000502:physiology; D040921:Stress Disorders, Traumatic; D013373:Substance P / Q000187:drug effects* / Q000502:physiology; D014839:Vomiting / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*
D000932:Antiemetics; D000970:Antineoplastic Agents; D009025:Morpholines; D018040:Receptors, Neurokinin-1; D000077608:Aprepitant; D012701:Serotonin; D013373:Substance P